Tissue Product Distributors Disappoint RTI, May Prompt Sales Autonomy
This article was originally published in The Gray Sheet
Executive Summary
Regeneration Technologies, Inc. (RTI) will consider creating an independent sales force after Medtronic placed fewer orders during Q1, causing RTI spinal revenue to drop by nearly half
You may also be interested in...
RTI’s Silver Lining: Sterling Bone Void Approval Sends Stock Up 21% In August
Regeneration Technologies' receipt of FDA clearance for the Sterling xenograft bone void fillers helped push the firm's stock price up 21% to $9.25 in August
RTI’s Silver Lining: Sterling Bone Void Approval Sends Stock Up 21% In August
Regeneration Technologies' receipt of FDA clearance for the Sterling xenograft bone void fillers helped push the firm's stock price up 21% to $9.25 in August
RTI Talking With Potential Acquirer, Seeking Clearance For Xenograft Implant
Regeneration Technologies, Inc.'s compliance with FDA's Good Tissue Practice regulations may have piqued the interest of a potential acquirer or strategic partner with whom the biologics manufacturer apparently is in discussions